Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-179 + JZP-3507
- Development stage
- Preclinical
- Lead developer
- Curtana Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CT-179 + JZP-3507 is an investigational combination therapy being evaluated for the treatment of brain cancers, specifically diffuse midline glioma (DMG). The combination consists of CT-179, a brain-penetrant, orally active small molecule inhibitor of oligodendrocyte transcription factor 2 (OLIG2) developed by Curtana Pharmaceuticals, and JZP-3507 (also known as zeltiprone or ONC206), an orally bioavailable imipridone derivative developed by Jazz Pharmaceuticals that acts as a dual mitochondrial caseinolytic protease P (ClpP) agonist and dopamine receptor D2 (DRD2) antagonist. Preclinical studies in patient-derived models of diffuse midline glioma have demonstrated that combining the OLIG2-targeting mechanism of CT-179 with the mitochondrial stress-inducing and DRD2-antagonizing effects of JZP-3507 results in synergistic anti-tumor efficacy, promoting apoptosis and inhibiting tumor growth.
- Other names
- CT-179 + JZP3507CT-179 + ONC-206CT-179 + ONC206CT-179 + zeltiproneCT179 + JZP-3507CT179 + JZP3507CT179 + ONC-206CT179 + ONC206CT179 + zeltiproneJZP-3507 + CT-179ONC206 + CT-179zeltiprone + CT-179
02
Targets
AURKA (Aurora kinase A)CDC20 (Cell division cycle protein 20 homolog)CDCA8 (Cell division cycle-associated protein 8)CLPP (Caseinolytic mitochondrial matrix peptidase proteolytic subunit)CXCL10 (C-X-C Motif Chemokine Ligand 10)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)EGFR (Epidermal growth factor receptor)HDAC7OLIG2 (Oligodendrocyte transcription factor 2)CD274 (Programmed cell death protein 1 ligand 1)PDGFR (PDGFR family)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on CT-179 + JZP-3507.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-179 + JZP-3507.